HGH 191AA (Somatropin)

Protocol examples

Protocol logic check

Independent evidence

Regulatory status: approved drug label available for somatropin products

Storage

Norditropin and Genotropin products are generally refrigerated 2-8 C before use; in-use limits vary by product/strength. Genotropin reconstituted cartridges are refrigerated and discarded after 28 days.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Active cancer or evidence of neoplastic activity: exogenous GH and IGF-1 directly accelerates tumor cell proliferation; GH should not be initiated or continued if active malignancy is detected.
• Intracranial lesions that are not fully inactive and treated: antitumor therapy must be complete prior to GH initiation.
• Insulin resistance or pre-existing type 2 diabetes: HGH is diabetogenic at therapeutic doses; progressively worsens insulin sensitivity; fasting glucose must be monitored throughout.
• Diabetic ketoacidosis.
• Proliferative or severe non-proliferative diabetic retinopathy: GH/IGF-1 elevation worsens retinal vasculopathy.
• Concurrent use with CJC-1295 No DAC, CJC-1295 DAC, ipamorelin, tesamorelin, GHRP-2, GHRP-6, or sermorelin: redundant and counterproductive GH axis stimulation; secretagogues stimulate a pituitary that exogenous HGH has already suppressed.
• Acute critical illness: increased mortality observed in critically ill patients (open heart surgery, abdominal surgery, multiple trauma, acute respiratory failure) receiving high-dose GH; do not use in ICU or perioperative settings.
• Pregnancy: limited human data; use only if clearly needed; associated with fetal risks in animal studies.
• Breastfeeding: not known whether excreted in human milk; caution advised.
• Known hypersensitivity to somatropin or excipients (including benzyl alcohol in some formulations: absolute contraindication in newborns).
• Active acromegaly: exogenous GH in already-excess GH state.
• Closed epiphyses in pediatric patients being treated for growth failure: dose adjustment required.
• Concomitant high-dose glucocorticoid therapy: inhibits IGF-1 production and growth-promoting effects; glucocorticoid replacement doses should be carefully adjusted.
• Concomitant CYP450-metabolized drugs: GH increases CYP450 clearance; adjust cyclosporine, sex steroids, anticonvulsants as needed.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.

• Water retention and peripheral edema: the most commonly reported early adverse effect; GH-mediated sodium and fluid retention; typically most pronounced in the first 4-8 weeks; responsive to dose reduction.
• Arthralgia (joint pain): GH-mediated periarticular fluid accumulation; particularly wrists, knees, and ankles.
• Myalgia (muscle pain): GH-related; typically transient.
• Carpal tunnel syndrome: GH-mediated median nerve compression from fluid retention; more common in adults; may require dose reduction or discontinuation.
• Paresthesia (tingling/numbness): in hands and feet; from GH-related fluid pressure on peripheral nerves.
• Decreased insulin sensitivity: progressive with dose and duration; the primary metabolic adverse effect of sustained exogenous GH; monitor fasting glucose.
• Elevated fasting blood glucose: direct consequence of GH-induced insulin resistance.
• Peripheral swelling (hands, feet, face): edema, particularly in the first weeks.
• Headache: vasodilation and fluid shifts.
• Benign intracranial hypertension: rare; typically in pediatric patients; presents as headache, visual changes, nausea; resolves with dose reduction.
• Lipoatrophy at injection sites: with prolonged injection at the same site; rotate injection sites to prevent.
• Pituitary suppression of endogenous GH: exogenous GH suppresses the HPG axis; gradual taper required upon cycle cessation to allow pituitary recovery.
• Hypothyroidism: GH may reduce T4 to T3 conversion; monitor thyroid function with extended cycles.
• Antibody formation: in rare subjects; typically low binding capacity and not clinically significant.
• Gynecomastia: rare; associated with GH-induced IGF-1 elevation and secondary prolactin effects.
• Diabetes mellitus: with sustained supraphysiologic doses in predisposed subjects.
• Leukemia risk: reported in small number of pediatric patients; relationship to GH therapy uncertain; caution in subjects with prior malignancy.
• Injection site reactions: pain, redness, swelling at subcutaneous sites; short-term and localized.

Compatibility

The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa9d3467-a450-4b06-885a-7d834dcbddff
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ffebf88b-d257-4542-9808-74d9b7167765
• PubMed search: HGH 191AA (Somatropin)
• DailyMed label search: somatropin